University of North Dakota

UND Scholarly Commons
Nursing Capstones

Department of Nursing

7-26-2017

Gabapentin Administration in Patients Undergoing
Surgical Procedures
Kirsten G. Boekelheide

Follow this and additional works at: https://commons.und.edu/nurs-capstones
Recommended Citation
Boekelheide, Kirsten G., "Gabapentin Administration in Patients Undergoing Surgical Procedures" (2017). Nursing Capstones. 165.
https://commons.und.edu/nurs-capstones/165

This Independent Study is brought to you for free and open access by the Department of Nursing at UND Scholarly Commons. It has been accepted for
inclusion in Nursing Capstones by an authorized administrator of UND Scholarly Commons. For more information, please contact
zeineb.yousif@library.und.edu.

Running head: GABAPENTIN ADMINISTRATION

GABAPENTIN ADMINISTRATION IN PATIENTS UNDERGOING SURGICAL
PROCEDURES
By
Kirsten G. Boekelheide
Bachelor of Science in Nursing, University of North Dakota, 2012

An Independent Study
Submitted to the Graduate Faculty
of the
University of North Dakota
in partial fulfillment of the requirements
for the degree of
Master of Science

Grand Forks, North Dakota
February
2017

GABAPENTIN ADMINISTRATION

2
PERMISSION

Title

Gabapentin Administration in Patients Undergoing Surgical Procedures

Department

Nursing

Degree

Master of Science

In presenting this independent study in partial fulfillment of the requirements for a
graduate degree from the University of North Dakota, I agree that the College of Nursing
and Professional Disciplines of this University shall make it freely available for
inspection. I further agree that permission for extensive copying or electronic access for
scholarly purposes may be granted by the professor who supervised my independent
study work or, in his absence, by the chairperson of the department or the dean of the
School of Graduate Studies. It is understood that any copying or publication or other use
of this independent study or part thereof for financial gain shall not be allowed without
my written permission. It is also understood that due recognition shall be given to me and
to the University of North Dakota in any scholarly use which may be made of any
material in my independent study.

Signature __________________________

Date ______________________________

GABAPENTIN ADMINISTRATION

3
Abstract

Title:

Gabapentin Administration in the Patient Undergoing Surgical Procedures

Background: A 75-year-old male patient undergoing elective total knee arthroscopy,
received 600 mg of oral gabapentin pre-operatively. With multiple comorbidities, a spinal anesthetic was not an option, and the surgeon
preferred a femoral block not be completed. In an effort to avoid
significant post-operative narcotic use, gabapentin was administered preoperatively. Gabapentin is a gamma-aminobutyric acid mimetic
medication. It has historically been utilized in the areas of adjunctive
seizure treatment and management of post-herpetic and other nerve related
pain, but has been found to have analgesic properties. With its low side
effect profile, the medication has drawn the attention of anesthesia
providers to be utilized in the perioperative setting as part of multimodal
pain management care plans.
Purpose:

To evaluate current recommendations for anesthesia providers regarding
gabapentin use in the perioperative setting.

Process:

A systematic search was conducted utilizing online search engines
CINAHL and PubMed for research articles, as well as anesthesia
textbooks, in an effort to find recently published material pertaining to
gabapentin use in the perioperative setting. Information was utilized from
the review of literature to cultivate evidence-based recommendations on
the inclusion of gabapentin in multimodal anesthesia care plans.

Results:

While more research is needed regarding standardized dosing regimens,
studies show gabapentin is useful in the perioperative setting as part of a
multimodal pain management plan.

Implications: Anesthesia providers should be well-versed in the use of gabapentin in the
perioperative setting. Its use should be determined on a case-by-case basis
to ensure individualized patient care.
Keywords:

gabapentin, pain, perioperative setting, anesthetic management

GABAPENTIN ADMINISTRATION

4
Background

Pain control is a very important component in the perioperative setting. It is a major
factor in patient recovery time and overall patient satisfaction. With more healthcare financing
institutions moving towards utilizing patient satisfaction in the funding equation, it becomes
imperative that every effort be made to adequately control patients’ pain. A multi-modal pain
management course should be employed by those providing anesthesia care to help attenuate the
discomforts of surgery. Gabapentin, a gamma-aminobutyric acid mimetic medication, has been
shown to be useful in this effort.
Gabapentin was first developed to imitate the structure of gamma-aminobutyric acid, a
neurotransmitter. In 1994, it was approved by the United States Food and Drug Association
(FDA), as an adjunct to anti-seizure medication regimens. While the drug was originally created
in an effort to help control seizures, this is actually it’s least marketed area of use today (Sirven,
2010). Gabapentin has also been FDA approved for postherpetic neuralgia and other nerve
related pain (Sirven, 2010). Because of its unique properties, gabapentin has proven itself useful
in multi-modal anesthesia care plans.
Since the practice of utilizing gabapentin in the perioperative setting has been suggested,
much research has been completed on this specific area of the drug’s use. The development of
gabapentin use in the perioperative setting is exciting, as this medication offers pain
management, a low side-effect profile, and reduction of post-operative opioid consumption
(Tiippana, Hamunen, Kontinen, & Kalso, 2007). It is important for anesthesia providers to be
well-versed on gabapentin and consider its use when developing a perioperative plan of care for
their patients.
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Case Report

A 75-year-old male presented for an elective left total knee arthroplasty, with a diagnosis
of degenerative joint disease of the knee. The patient was 180 cm and 107.6 kg, with a body
mass index (BMI) of 34. Significant medical history included type 2 diabetes mellitus, lung
cancer, peripheral vascular disease, hypertension, coronary artery disease, aortic stenosis, and
hyperlipidemia. Surgical history included an abdominal aortic aneurysm repair, a thoracotomy,
bilateral carotid endarterectomy, mediastinoscopy, coronary artery bypass grafting, cardiac stent
placement, and right total knee arthroplasty. The patient had allergies to lisinopril, flonase,
simvastatin, levoquin, levofloxacin, and fluticasone propionate. Home medications included
amlodipine, aspirin, clopidogrel, losartan, metformin, metoprolol succinate, multivitamin, niacin,
and pravastatin sodium. Pre-operative vital signs consisted of a blood pressure of 135/80 mmHg,
heart rate of 75 beats per minute, respiratory rate of 18 breaths per minutes, temperature of 36.4
degrees Celsius, and oxygen saturations of 97% on room air. Pre-operative laboratory data
included blood sugar of 158 mg/dL, sodium of 136 mEq/L, potassium of 4.6 mEq/L, blood urea
nitrogen of 21 mg/dL, creatinine of 1.0 mg/dL, chloride of 104 mEq/L, carbon dioxide of 23
mEq/L, anion gab of 9 mEq/L, calcium of 9.8 mg/dL, hemoglobin of 12.7 g/dL, hematocrit of
36.5%, and platelets of 157,000/microliter. The patient’s blood type was found to be O positive,
and negative for antibodies. Mallampati classification was assessed as a 2 pre-operatively, with
an ASA classification of 3.
The plan was to perform general anesthesia with a normal induction sequence, and place
an endotracheal tube. This plan was chosen over a spinal anesthetic with sedation because the
patient had not withheld his home medication, clopidogrel, for the recommended length of time.
Also, per surgeon preference, a femoral nerve block was not performed. Pre-operatively, 600 mg
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oral gabapentin was administered 30 minutes before the procedure. There would be no postoperative doses administered. In addition to the gabapentin, the patient received 975 mg oral
acetaminophen prior to the start of his procedure.
Once in the operating room, the standard non-invasive monitors were applied, vital signs
were found to be stable. Pre-oxygenation and denitrogenation was completed by having the
patient breathe 100% oxygen through a mask. The patient was then induced intravenously,
through a 20- gauge intravenous catheter, with 100 mcg Fentanyl, 150 mg propofol, and 50 mg
Rocuronium. Utilizing a Mac 4 blade, a Cormack-Lehane grade 1 view was visualized, and a
size 8.0 endotracheal tube was placed with one attempt. Placement was verified by condensation
appearance within the tube, bilateral chest rise and breath sounds, and end-tidal carbon dioxide.
The tube was secured and the patient’s eyes were lubed and taped. The anesthetic was
maintained with sevoflurane 2% with a mixture of 1.0 L/min of oxygen and 1.0 L/min of air.
Mechanical ventilation was applied with an auto-flow volume control mode utilizing a tidal
volume of 650 mL, rate of 12 breaths/min, and a positive end-expiratory pressure of 5 cm/H2O.
Following induction, the patient was supinely placed with all positioning concerns
corrected and verified, and all pressure points padded. The patient received 2 grams of cefazolin
prior to incision. During the maintenance phase, the patient received 15 mg of ephedrine, 250
mcg of Fentanyl, and 1200 mL of lactated ringers. The surgeon did utilize a tourniquet which
was inflated for 82 minutes. Blood loss was estimated to be less than 50 mL. The nondepolarizing muscle relaxant was reversed, after confirming presence of at least one twitch on
train of four monitoring, with 0.8 mg of glycopyrulate and 5 mg of neostigmine. To prevent
post-operative nausea and vomiting, 4 mg of ondansetron was administered towards the end of
the case. The patient went through emergence without difficulty and was extubated in the
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normal fashion after confirmation of command following, regular depth and rate of breathing,
and stable vital signs.
The patient was transported to the post-anesthesia care unit, and then transferred to the
orthopedic medical floor. Within the first two hours following his operation, the patient received
100 mcg fentanyl in divided doses. He then started taking 1-2 10 mg hydrocodone/325 mg
acetaminophen tablets approximately every 4 hours. At 0500 on post-operative day one, the
patient received 0.4 mg hydromorphone IV, after he had not received pain medicine for 6 hours
while sleeping. At 0830 on post-operative day one, the patient reported minimal surgical pain,
with a current rating of 4/10. He mentioned that after a full night of sleep, the pain was a “little
worse in the morning,” but “was very tolerable.” The patient continued receiving 1-2 tablets of
10 mg hydrocodone/325 mg acetaminophen every 4-6 hours throughout his hospital stay.
Without post-surgical complications, the patient was discharged home on post-operative day two
with prescriptions for subcutaneous enoxaparin sodium and oral 10 mg hydrocodone/325 mg
acetaminophen.
Discussion
Adequate post-operative pain control has received much attention in the last decade.
There has been a widespread understanding across multiple disciplines, including not only
clinicians, but economists and health policy experts as well, that acute pain following surgical
procedures is undertreated (Miller et al., 2015). In 1992, this issue drove the United States
Department of Health and Human Services Agency for Healthcare Quality and Research to
develop a national clinical practice guideline for the management of acute pain. It is a landmark
document that includes the acknowledgement of the inadequacies of perioperative pain control,
the importance of adequate pain control, and the need for providers to stay accountable for their
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patient’s pain experience. Because of this, national standards regarding perioperative pain
management were developed by which providers are now measured against (Miller et al., 2015).
It is imperative that anesthesia providers use their expertise in pain management to be at the
forefront of advancements in this area of medicine.
Because pain management is, and will always be, a main concern of anesthesia providers,
it is important to employ multimodal strategies when dealing with patients in the perioperative
setting. One important adjunct to a pain related plan of care is gabapentin. Gabapentin is
becoming more and more attractive for anesthesia use in the perioperative setting because of its
unique mechanism of action. In the following paragraphs, pain physiology, pain management,
and gabapentin’s place in pain control will be discussed.
Pain Physiology
Pain is an experience that varies significantly from patient to patient. It is very complex
and often difficult to outline. The International Association for the Study of Pain (IASP) has
defined pain as “an unpleasant sensory and emotional experience associated with actual or
potential tissue damage” (2012). Pain classification is usually based upon longevity (whether the
pain is acute or chronic), and the underlying pathophysiology (whether the pain is nociceptive or
non-nociceptive) (Nagelhout & Plaus, 2014).
Nociceptive pain is often referred to as pain arising from the stimulation of nerve cells in
contrast with non-nociceptive pain, which involves messages of pain regardless of noxious
stimuli. Nociceptive pain can then be further categorized into somatic or visceral pain. Somatic
pain has an identifiable localization, and is a result of actual damage to tissue, leading to the
release of pain-mediating chemicals from the injured cells (Nagelhout & Plaus, 2014). Visceral
pain is more diffuse. It is often described as dull or aching, in contrast to the sharp, localized,
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stabbing nature of somatic pain. Visceral pain is associated with the distention of an organ
capsule or some kind of obstruction in normally hollow viscera. At times, visceral pain can be
associated with an autonomic response, invoking feelings of nausea and diarrhea (Nagelhout &
Plaus, 2014).
Non-nociceptive pain is categorized as being either neuropathic or idiopathic.
Neuropathic pain refers to a disorder of the central nervous system caused by damage to neural
structures. This causes painful stimuli to be abnormally processed. “Burning” or “tingling” are
words often used to describe neuropathic pain (Nagelhout & Plaus, 2014). Idiopathic pain is a
term used to describe pain that has no apparent cause. There is no mechanism identifiable for the
pain, and there are often psychological symptoms present as well (Nagelhout & Plaus, 2014).
The anatomy and physiology of pain is quite complex. Surgery produces an obvious
tissue injury, with subsequent release of inflammatory mediators. These go on to activate
peripheral nociceptors (pain receptors), which initiate the transduction and transmission of
nociceptive information to the central nervous system (Miller et al., 2015)
The first of four commonly referred to processes of a pain response is transduction. This
occurs when a noxious stimulus is detected by the free nerve endings of nociceptors, and an
action potential is produced. The peripheral nociceptors are categorized according to diameter,
myelination, and conduction velocity, and transfer the noxious stimuli to the dorsal horn of the
spinal cord (Nagelhout & Plaus, 2014). Also at this time, there is a release of inflammatory
chemical mediators and neurotransmitters, arising from the free nerve endings of the nociceptors.
Some of the more prominent of these include Substance P, Glutamate, Bradykinin, Histamine,
Serotonin, Prostaglandins, and Cytokines. These chemical mediators and neurotransmitters cause
an influx of sodium ions to enter nerve fiber membranes leading to depolarization. There is also
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an efflux of potassium ions, subsequently leading to repolarization. This process creates an
action potential, thereby generating a pain impulse (Nagelhout & Plaus, 2014).
Transmission is the second process involved in pain. This process describes how an
action potential is conducted from the periphery to the central nervous system. Utilizing the
spinothalamic system, afferent neurons (which have cell bodies located in the dorsal root ganglia
of the spinal cord) enter the dorsal cord. Here the fibers are said to be in the tract of Lissauer,
and either ascend or descend several spinal segments (Nagelhout & Plaus, 2014). After the
fibers leave the tract of Lissauer, the axons of these afferents enter the gray matter of the dorsal
horn. It is here that they synapse with second-order neurons, primarily terminating in Rexed’s
laminae I, II and V (Nagelhout & Plaus, 2014). Next, second-order neurons cross the midline of
the spinal cord, and ascend the spinothalamic tract to the thalamus. It is here that the secondorder neurons synapse with third-order neurons, which then send projections to the cerebral
cortex (Nagelhout & Plaus, 2014).
The cerebral cortex is where the third process of pain, perception, occurs. Perception
occurs when certain areas of the brain, including the amygdala, somatosensory areas of the
cortex, the hypothalamus, and the anterior cingulate cortex, recognize the pain signal. This
causes the actual realization of pain (Nagelhout & Plaus, 2014).
Finally, modulation of the pain transmission is a process that involves either suppression
or enhancement of the pain signals. Suppression occurs through descending efferent pathways,
which are often described as the body’s own analgesia system (Nagehout & Plaus, 2014). When
the efferent pathway is stimulated with a noxious event, descending axons from the cerebral
cortex, hypothalamus, thalamus, periaqueductal gray area (PAG), nucleus raphe magnus (NRM),
and locus coeruleus synapse with and suppress pain transmission in the brainstem and dorsal
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horn of the spinal cord (Nagelhout & Plaus, 2014). In addition, several neurotransmitters and
their receptors play roles in the inhibitory modulation of pain. These include endogenous
opioids (encephalin/dynorphin), glycine, norephinephrine, serotonin, and gamma-amino-butyric
acid (GABA). Many pain related pharmacotherapies are directed at these neurotransmitters and
their receptors (Nagelhout & Plaus, 2014).
Pain and Surgery
In general, the pain involved in the perioperative setting is acute pain. The intensity of
acute pain should diminish over the course of healing and is self-limited. It is responsive to
pharmacotherapy and the treatment of its initiating cause (Nagelhout & Plaus, 2014). More than
80% of patients who undergo surgical procedures experience acute post-operative pain, with
75% of these patients rating their pain as moderate, severe, or extreme (Chou et al., 2016).
Unfortunately, less than half of patients who undergo surgical procedures state their pain was
adequately controlled post-operatively (Chou et al., 2016).
When pain is not adequately treated in the post-operative setting, it causes multiple, welldocumented adverse effects involving multiple organ systems. The increased release of
catecholamines and cortisol produce an increase in heart rate, an increase in vascular resistance,
an increase in myocardial contractility, and an increase in arterial blood pressure. These
responses will ultimately increase myocardial oxygen consumption and demand. With the
increased demand in oxygen, the patient may experience dysrhythmias, angina, myocardial
ischemia, and myocardial infarction. While these implications have the potential to be
detrimental in a healthy patient, they could cause severe repercussions in those individuals with
an already compromised cardiovascular system (Nagelhout & Plaus, 2014).
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Inadequate pain management can also negatively affect the respiratory system. For some,
post-operative respiratory function is markedly decreased, especially in those who have
undergone thoracic or upper abdominal surgery (Miller et al., 2015). Patients may experience
decreases in tidal volumes, vital capacity, inspiratory capacity, and functional residual capacity.
When patients are experiencing pain, it is an innate response to limit movement in an attempt to
minimize the unpleasant feeling. However, this is detrimental, as limiting physical activity or
coughing post-operatively can lead to atelectasis and pneumonia (Nagelhout & Plaus, 2014).
Nociceptive stimuli to the CNS from the periphery leads to the neuroendocrine stress
response. This is when a combination of local inflammatory substances and systemic mediators
are released, and there is an increase in catabolic hormone secretion with a decreased secretion of
anabolic hormones (Miller et al., 2015). Catabolic hormone release without an antagonizing
anabolic hormone release leads to higher levels of cortisol, antidiuretic hormone, glucagon,
aldosterone, renin, and others. This response creates sodium and water retention, increased
blood glucose levels, and increased lactate levels (Miller et al., 2015). In addition, a
hypermetabolic state occurs, increasing oxygen demand and mobilizing metabolic substrates
from storage. This stress response is detrimental to healing, and prolongs recovery time (Miller
et al., 2015).
If acute post-surgical pain is left untreated, the continuous release of inflammatory
mediators actually sensitizes functional nociceptors and triggers dormant ones, leading to an
increased rate of discharge from a decreased threshold for activation. While not well understood,
this effect can cause functional changes in the dorsal horn of the spinal cord and lead to chronic
pain after acute surgical injury (Miller et al., 2015).
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Pain can also decrease gastric emptying leading to nausea and vomiting, as well as cause
urinary retention and oliguria by increasing urinary sphincter tone. If allowed to persist,
gastrointestinal return to function may become delayed, even leading to paralytic ileus (Miller et
al., 2015). Additionally, pain can increase platelet aggregation and venous stasis leading to
thrombosis and DVT/PE. Furthermore, unresolved pain can impair immune function, leading to
increased infection rates (Nagelhout & Plaus, 2014).
In addition to the physical effects, pain can have significant psychological effects for
patients such as fear, anxiety, depression, anger, and feelings of helplessness (Nagelhout &
Plaus, 2014). The consequences of inadequate post-operative pain management include a
delayed recovery, an increase in healthcare costs, a reduction in functional reclamation, and a
negative patient perception of his/her healthcare experience. All of which lead to reduced
satisfaction with care (Chou et al., 2016; Nagelhout & Plaus, 2014).
Multimodal Pain Management
It is imperative that anesthesia providers be at the forefront of management of acute pain
in the perioperative setting. Anesthesia providers have a responsibility to participate in the
assessment, management, and treatment of pain, and to utilize strategies to individualize plans of
care for their patients. This is where multi-modal pain management is important.
The American Society of Anesthesiologists (ASA) strongly recommends exercising a
multimodal approach whenever possible based on individual patient needs. The ASA defines
multimodal techniques for pain management as those that, “include the administration of two or
more drugs that act by different mechanisms for providing analgesia, the drugs may be
administered via the same route or by different routes” (2012, p. 253). In addition, the Journal of
Pain featured post-operative pain management recommendations from a panel of prestigious
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organizations, which included the utilization of multimodal pain strategies for the best patient
satisfaction and outcomes. In this specific article, Chou and his colleagues defined multimodal
pain management as, “the use of a variety of analgesic medication and techniques that target
different mechanisms of action in the peripheral and/or central nervous system” (2016, p. 136).
It goes on to reveal that, based on the research completed by the panel, multimodal pain
management may have additive or synergistic effects, rendering it more effective at relieving
pain than single-modality interventions (Chou et al., 2016).
Multimodal pain management is important as it can reduce the side-effect profile that
may come with utilizing a single-modality approach. This effect is most commonly seen with
reducing the respiratory depression and/or the nausea and vomiting that may come with the
administration of opiates (Helander et al., 2017). By taking advantage of analgesia production
through different cellular pathways, the anesthesia provider is able to offer a more complete plan
of care to their patients including optimized pain relief, minimization of side effects, and timely
discharge. Multimodal pain management allows early mobilization, early nutrition, and early
attenuation of the perioperative stress response (Miller et al., 2015)
When implementing multimodal anesthesia, important additions to the traditional opiatebased analgesia regimens to consider include NSAIDs, acetaminophen, ketamine, alpha-2
agonists, glucocorticoids, and gabapentinoids (Helander et al., 2017). Tiippana, Hamunen,
Kontinen, & Kalso point out that local anesthetics/regional anesthesia may be appropriate
choices when assembling a multimodal approach to pain management post-operatively (2007).
The ASA also suggests combining regional blockades as indicated to provide the best anesthetic
experience possible for their patients (2012).
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The multimodal approach not only helps alleviate postoperative pain, it may lead to
shorter intubation times, earlier return of bowel function, decreased risk of chronic postoperative pain development, and a preservation of total body protein to aid the healing process.
It lessens recovery time, helping more patients qualify for early hospital discharge (Miller et al.,
2015). Multimodal pain management integrates the most recent data and techniques, aiding
institutions in increasing patient satisfaction while remaining economically sound (Miller et al.,
2015).
Gabapentin
Chemical make-up
Gabapentin [1-(aminomethyl) cyclohexane acetic acid] is a gamma-aminobutyric acid
(GABA)-mimetic compound. GABA, with regard to pain modulation, is an inhibitory
neurotransmitter released via the descending pathway. In this way, it is able to suppress
ascending pain signals, decreasing pain sensation (Nagelhout & Plaus, 2014). GABA receptors
in the body utilize signal transduction, otherwise known as secondary messenger pathways.
Secondary messenger pathways are processes in which a cell converts one signal or stimulus,
into another. They may also involve specifically ordered sequences or cascades of events. Many
of our commonly used anesthetic medications work in this fashion, including gabapentin
(Nagelhout & Plaus, 2014).
While gabapentin is technically a synthesized form of GABA, it exerts no GABA agonist
effects and it does not inhibit GABA uptake or degradation. Gabapentin is a structural analogue
of the neurotransmitter, GABA, with a cyclohexane ring added to its chemical make-up (Rose &
Kam, 2002). Gabapentin’s molecular weight is 174.34 and it is stable at room temperature. At a
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physiologic pH, it is highly charged and exists as a zwitterion. It is bitter tasting and is a white
crystalline substance (Rose & Kam, 2002).
Gabapentin, as a medication, is only available in an oral preparation. It possesses a high
lipid solubility, and does not significantly partake in protein binding, with less than 3% of
circulating drug found bound to plasma proteins (Kim et al., 2016). It has been assigned an FDA
pregnancy risk category of “C,” meaning risk of use during pregnancy cannot be ruled out. This
is because adequate human studies in the area are lacking and animal studies have shown risk to
the fetus in rare instances. Although there is a chance the drug may cause fetal harm, potential
benefits of administration during pregnancy may outweigh the potential risk. In addition,
gabapentin is distributed into breast milk with oral administration. (Kim et al., 2016).
Mechanism of Action
Gabapentin’s mechanism of action is still not completely clear. Researchers do
understand that the drug blocks voltage-gated calcium channels by binding to the alpha-2-delta
subunits on the pre-synaptic side, reducing calcium influx (Miller et al., 2015).
Calcium channels are important to consider when thinking about analgesic medication
administration. The opening of these channels facilitates the release of neurotransmitters from
presynaptic sites; and when the concentration of intracellular calcium shifts, cell membrane
excitability is modulated, triggering a cascade of intracellular responses (Miller et al., 2015).
These voltage-gated calcium channels regulate a variety of actions in the body, playing a
significant role in both nociceptive and anti-nociceptive processes. After a pain-evoked action
potential is triggered, the influx of calcium through voltage-gated calcium channels causes a
fusion of the synaptic vesicle and the neuronal membrane. This leads to the release of
neurotransmitters in the dorsal horn of the spinal cord (Schmidt, Ruchelli, Mackey, Carroll, &
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Epi, 2013). By blocking/reducing calcium influx through modulation of this process, gabapentin
produces a reduction in the release of pain-causing neurotransmitters (e.g. glutamate) from
nociceptive afferents (Miller et al., 2015; Yan, Butler, Kurowski, & Perloff, 2014). In addition,
it is hypothesized that gabapentin may also exert analgesic effects by activating descending,
inhibitory pain pathways (Schmidt et al., 2013).
Pharmacokinetics
Gabapentin is absorbed only in the small intestine. Its absorption is limited to a relatively
small part of the duodenum (Schmidt et al., 2013). The process is a combination of diffusion and
facilitated transport. As mentioned previously, the drug is only available in oral form. Upon
oral administration, the drug binds to a receptor (as yet to be fully identified) which is linked to a
saturable L-amino acid transport mechanism (Rose & Kam, 2002). Because of the saturability of
this carrier-dependent transport system, gabapentin’s bioavailability varies inversely with its
administration dose (Khahi, Yaghooti, Marashi, & Nadjafi, 2011). This means that the
bioavailability of a 300 mg dose of gabapentin is higher than that of a 600 mg dose.
Gabapentin’s dose-dependent saturable absorption indicates that as the dose is increased, a lesser
percentage of the drug is actually available for absorption. As the active transport mechanism
for gabapentin in the duodenum reaches peak saturation, progressively higher levels of
gabapentin ingestion yield progressively smaller blood concentrations (Schmidt et al., 2013).
Peak plasma levels of the drug are achieved approximately 2-3 hours after ingestion, with peak
cerebrospinal fluid levels occurring at 4-6 hours after ingestion (Rose & Kam, 2002; Schmidt et
al., 2013).
Gabapentin has an extensive volume of distribution, indicating it has an extensive amount
of tissue distribution, as well as minimal protein binding (Schmidt et al., 2013). Its cerebral
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spinal fluid concentrations are 20% of plasma concentrations, and brain concentrations are 80%
of plasma concentrations (Rose & Kam, 2002). Gabapentin is actually not metabolized in
humans and is eliminated unchanged in the urine. Renal impairment will decrease gabapentin
elimination, as it follows a first-order kinetic elimination process in a linear fashion. This
correlates well with creatinine clearance levels (Rose & Kam, 2002). Gabapentin has an
elimination half-life that ranges from 4.8 to 8.7 hours (Schmidt et al., 2013). The drug is
eliminated with hemodialysis, so it should be administered after treatments to maintain a steady
state. Also, along with gabapentin’s lack of hepatic metabolism comes a lack of induction or
inhibition of hepatic microsomal enzymes. With this attribute, gabapentin does not cause
significant drug interactions (Rose & Kam, 2002).
Side Effects
Over considerable research, gabapentin has been found to boast a low side effect profile.
Because of the duodenal receptor saturation properties of gabapentin, there seems to be a limit
placed on its efficacy in comparison to those medications without transporter saturations
affecting absorption. This same concept can be applied as a favorable attribute to gabapentin’s
drug profile, in that there is an upper border placed on adverse effect potential (Schmidt et al.,
2013).
The most common side effects of gabapentin appear to be somnolence/sedation and
dizziness, with some relatively rare reports of ataxia, headache, visual disturbances, convulsions,
and peripheral edema (Rose & Kam, 2002; Schmidt et al., 2013). Should significant side effects
occur with gabapentin administration, often just decreasing the dose will help to attenuate any
adverse results. Data suggests that gabapentin administration may have a positive effect in
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actually reducing postoperative delirium, though this may also be attributed to subsequent
decreased opioid use (Schmidt et al., 2013).
Speaking to gabapentin’s safety profile is the practitioners’ ability to manage even
massive overdoses with supportive care alone (Schmidt et al., 2013). In extreme overconsumption, the patient could exhibit signs of severe ataxia, labored breathing, ptosis, sedation
or excitation, and hypo-activity. Treatment in overdose begins with airway protection and
includes any supportive measures needed in conjunction with presenting symptoms. Although
an overdose has been shown to be manageable, it is suggested that even asymptomatic patients
be observed for at least 4-6 hours (Kim et al., 2016).
While gabapentin has relatively minimal drug to drug interactions, there are some that are
noteworthy. One such interaction is gabapentin’s relationship to antacids. Antacid
administration can significantly impair the absorption of gabapentin by up to 20%, even when
the medications are given greater than two hours apart (Kim et al., 2016). This concept should
be considered when utilizing gabapentin in perioperative situations requiring the use of antacids,
such as bicitra (Schmidt et al., 2013). In addition, morphine and hydrocodone have both been
found to increase the AUC value (plasma concentration levels plotted against time) of
gabapentin, when given concomitantly. Decreases in either of these and/or gabapentin may be
necessary to avoid central nervous system depression. This is especially true for the relationship
between gabapentin and morphine (Kim et al., 2016). Also, naproxen may increase the
absorption rate of gabapentin by up to 15%. Finally, as with many drugs, patients may
experience increased central nervous system depression if gabapentin is taken along with alcohol
consumption (or other central nervous system depressing agents) (Kim et al., 2016).
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Original use of Gabapentin
Gabapentin was originally synthesized to purposefully imitate the structure of the
neurotransmitter, gamma-aminobutyric acid. In 1994, the drug was first approved by the United
States FDA for use as an adjunctive anticonvulsant medication, to be added to anti-seizure
medication regimens in an effort to help control partial seizures. Ironically, despite the fact that
the drug was developed for seizure prevention, the smallest current market for gabapentin use is
in cases of epilepsy and seizure disorders (Sirven, 2010).
In 1998, a double blind, randomized, placebo-controlled trial revealed that postherpetic
neuralgia pain was decreased up to 33% after a 4-week gabapentin regimen. This study also
revealed that after an 8-week regimen of the drug, patients experienced improved sleep, quality
of life, and total mood quality (Yan, Butler, Kurowski, & Perloff, 2014). After more studies
were completed in the area of nerve pain treatment, the FDA approved gabapentin for the
treatment of post-herpetic pain and other nerve related pain in 2002 (Sirven, 2010).
While adjunctive treatment of seizure disorders and management of post-herpetic pain
and other nerve related pain are the two indicated uses for gabapentin currently approved by the
FDA, the drug has numerous off-label uses. Such uses include management of perioperative
pain, cancer pain, attention deficit disorder, restless leg syndrome, migraine headaches,
premenstrual syndrome, and anxiety related disorders (Sirven, 2010; Yan, Butler, Kurowski, &
Perloff, 2014).
Perioperative Gabapentin Use
Perioperative gabapentin administration can be employed in a variety of surgical
situations, ranging from orthopedic procedures to abdominal procedures to head and neck
procedures. The Journal of Orthopaedic Surgery and Research recently published a meta-
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analysis of randomized controlled trials which found that administration of gabapentin in the
perioperative course of a patient receiving a total hip arthroplasty was effective in decreasing
postoperative narcotic use and reducing pain scores (Han, Li, Jiang, Ma, & Ma, 2016).
Interestingly, the researchers found no difference in side effect profiles between those control
groups that received gabapentin and those who received a placebo. In fact, it was discovered that
there was less reported postoperative nausea and vomiting in the gabapentin group (Han et al.,
2016).
Khahi and colleagues completed a double-blind, randomized controlled clinical trial and
found that just 300 mg of pre-emptive gabapentin administration significantly decreased
postoperative pain two hours after patients had undergone an internal fixation of the tibia (2011).
Montazeri, Kashefi, and Honarmand found similar results in their study of postoperative pain
and morphine demand following lower extremity orthopedic surgery (2007). In this randomized,
double-blind study, patients either received 300 mg of gabapentin or a placebo two hours prior to
surgery. It was found that patients who had received gabapentin reported significantly lower
pain scores and exhibited reduced rescue analgesic requirements postoperatively (Montazeri et
al., 2007).
A systematic review and meta-analysis was completed to examine the evidence of preemptive use of gabapentin in abdominal hysterectomy procedures. A total of fourteen trials,
consisting of 448 cases in the gabapentin control group and 443 in the placebo control group,
met inclusion criteria. The authors found that preemptive administration of gabapentin was
effective in decreasing postoperative pain scores, decreasing postoperative narcotic consumption,
and decreasing postoperative nausea and vomiting (Alayed, Alghanaim, Tan, & Tulandi, 2014).
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As a final example, a recent systematic search was conducted investigating gabapentin
use in otorhinolaryngology, head, and neck surgery. It too, found that gabapentin appears to
have a significant beneficial effect on perioperative pain relief, as well as on analgesic
consumption. This effect was most prominent for those undergoing rhinologic and thyroid
surgery (Sanders & Dawes, 2016).
Gabapentin and Opioids
One of the most cited reasons for utilization of perioperative gabapentin is the ability to
utilize decreased quantities of opioids in an effort to treat postoperative pain. Opioids have
undesirable side effects, such as nausea, respiratory depression, and sedation. They also have the
increased potential for tolerance and addiction (Arumugam, Lau, & Chamberlain, 2016). While
multiple studies indicate gabapentin use is beneficial in decreasing perioperative opioid use,
Arumugam et al., completed a comprehensive literature search with the sole purpose of studying
this effect (2016). Seventeen randomized control trials met inclusion criteria, consisting of 1,793
patients. The researchers concluded that administration of preoperative gabapentin did reduce
opioid consumption in the first 24 hours following surgery. They go on to recommend clinicians
utilize gabapentin in multimodal treatment plans as an effective analgesic adjunct (Arumugam et
al., 2016)
Perioperative Dosing
Because of gabapentin’s pharmacokinetic profile, its use in perioperative pain
management should be initiated two hours before surgery in a pre-emptive manner. In this way,
it can be more effective in reducing postoperative pain, than if it were to be started early in the
postoperative period (Khahi et al., 2011). When considering the time gabapentin needs to reach
peak cerebrospinal fluid levels (4-6 hours), practitioners may even consider home administration
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the night before surgery. This effect may prove beneficial, but with the possibility of dizziness,
sedation or confusion, many choose to forego this strategy as it has not yet been formally
recommended (Schmidt et al., 2013).
Conversely, Schmidt and colleagues also found that preoperative dosing is not absolutely
critical for reducing immediate postoperative pain or opioid use (2013). Although, because most
completed studies on gabapentin use to manage acute perioperative pain include preoperative
dosing, it is still concluded that preoperative administration is desirable. However, failure to
provide a preoperative dose should not dissuade the practitioner from administration through an
oral gastric tube directly after incision or from immediate postoperative dosing (Schmidt et al.,
2013). Preoperative, intraoperative, or postoperative initial dosing have all shown to reduce
early postoperative pain. Difference in timing of gabapentin administration in relation to pain
attenuation and decreased opioid use seems to have minimal effect on outcomes, but more
research would be required before recommendations can be developed in this area (Schmidt et
al., 2013).
There have been relatively few comprehensive studies completed to address optimal
dosing instructions for perioperative gabapentin administration. While further research is needed
in order to determine the best method, existing studies find that higher preoperative doses, in
addition to postoperative doses, seems to be the most advantageous for patients. Schmidt and
colleagues suggest 1200 mg gabapentin be administered at least two hours prior to surgery,
followed by 600 mg every 8 hours for up to two weeks (2013). However, many studies indicate
their research was completed utilizing different dosing than this example. Optimal duration of
treatment is also yet unknown (Schmidt et al., 2013).
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Conclusion

In conclusion, the majority of recent research suggests perioperative gabapentin is a
beneficial medication for anesthesia providers to consider when contemplating a plan of care.
The drug has been shown to provide adequate post-operative pain management, while allowing
the patient to consume decreased doses of narcotic medication. It also boasts a low side effect
profile and minimal drug interactions, speaking to its exemplary safety profile. In the
aforementioned case study, gabapentin was pre-operatively administered to a patient undergoing
total knee arthroplasty. While there is no way to determine if his individual pain control was
aided by gabapentin specifically, based on the research the idea can be adopted as probable. It is
also noteworthy to mention that post-operative gabapentin doses may have added to the patient’s
pain control. The importance of patient satisfaction scores is increasing in all facets of
healthcare, including financial considerations for institutions performing surgical procedures. It
is apparent that gabapentin is a worthy addition to a multi-modal, operative pain management
plan. With adequate pain management, patient satisfaction scores can be expected to improve. It
would be prudent for anesthesia providers to become well-versed on gabapentin administration
and consider its use in developing patient specific plans of care.

GABAPENTIN ADMINISTRATION

25
References

Alayed, N., Alghanaim, N., Tan, X., & Tulandi, T. (2014). Preemptive use of gabapentin in
abdominal hysterectomy: A systematic review and meta-analysis. Obstetrics and
Gynecology, 123(6), 1221-1229.
American Society of Anesthesiologists. (2012). Practice guidelines for acute pain management in
the perioperative setting: An updated report by the American Society of
Anesthesiologists task force on acute pain management. Anesthesiology, 116(2), 248273.
Arumugam, S., Lau, C. S. M., & Chamberlain, R. S. (2016). Use of preoperative gabapentin
significantly reduces postoperative opioid consumption: A meta-analysis. Journal of Pain
Research, 9, 631-640.
Chou, R., Gordon, D. B, de Leon-Casasola, O. A., Rosenburg, J. M., Bickler, S., Brennan, T., . . .
Wu, C. L. (2016). Management of postoperative pain: A clinical practice guideline
from the American Pain Society, the American Society of Regional Anesthesia and Pain
Medicine, and the American Society of Anesthesiologists’ Committee on Regional
Anesthesia, Executive Committee, and Administrative Council. The Journal of Pain,
17(2), 131-157.
Han, C., Li, X., Jiang, H., Ma, J., & Ma, X. (2016). The use of gabapentin in the management of
postoperative pain after total hip arthroplasty: A meta-analysis of randomized controlled
trials. Journal of Orthopaedic Surgery and Research, 11(79).
Helander, E. M., Menard, B. L., Harmon, C. M., Homra, B. K., Allain, A. V., Bordelon,
G. J., . . . Kaye, A. D. (2017). Multimodal analgesia, current concepts, and acute pain
considerations. Current Pain and Headache Reports, 21(3).

GABAPENTIN ADMINISTRATION

26

International Association for the Study of Pain (IASP). (2012). IASP taxonomy. Retrieved from
http://www.iasp-pain.org/Taxonomy?navItemNumber=576#Pain
Khahi, P., Yaghooti, A. A., Marashi, S. H., & Nadjafi, A. (2011). Effect of pre-emptive
gabapentin on postoperative pain following lower extremity orthopaedic surgery under
spinal anesthesia. Singapore Medical Journal, 52(12), 879-882.
Kim, S., Thiessen, P. A., Bolton, E. E., Chen, J., Fu, G., Gindulyte, A., . . . Bryant, S. H. (2016).
PubChem Substance and Compound databases: Gabapentin. Retrieved from
https://pubchem.ncbi.nlm.nih.gov/compound/gabapentin#section=Information-Sources
Miller, R. D., Cohen, N. H., Eriksson, L. I., Fleisher, L. A., Wiener-Kronish, J. P., & Young, W.
L. (2015). Miller’s Anesthesia (8th ed.). Philadelphia, PA: Elsevier Saunders.
Montazeri, K., Kashefi, P., & Honarmand, A. (2007). Pre-emptive gabapentin significantly
reduces postoperative pain and morphine demand following lower extremity orthopaedic
surgery. Singapore Medical Journal, 48(8), 748-751.
Nagelhout, J. J., & Plaus, K. L. (2014). Nurse Anesthesia (5th ed.). St. Louis, MO: Elsevier
Saunders.
Rose, M. A., & Kam, P. C. A. (2002). Gabapentin: Pharmacology and its use in pain
management. Anaesthesia, 57, 451-462.
Sanders, J. G., & Dawes, P. J. (2016). Gabapentin for perioperative analgesia in
otorhinolaryngology-head and neck surgery: Systematic review. Otolaryngology – Head
and Neck Surgery, 155(6), 893-903.
Schmidt, P. C., Ruchelli, G., Mackey, S. C., Carroll, I. R., & Epi, M. S. (2013). Perioperative
gabapentinoids: Choice of agent, dose, timing, and effects on chronic postsurgical pain.
Anesthesiology, 119(5), 1215-1221.

GABAPENTIN ADMINISTRATION

27

Sirven, J. I. (2010). New uses for older drugs: The tales of aspirin, thalidomide, and gabapentin.
Mayo Clinic Proceedings, 85(6), 508-511.
Tippana, E. M., Hamunen, K., Kontinen, V. K., & Kalso, E. (2007). Do surgical patients benefit
from perioperative gabapentin/pregabalin? A systematic review of efficacy and safety.
International Anesthesia Research Society, 104(6), 1545-1556.
Yan, Z. Y., Butler, P. M., Kurowski, D., & Perloff, M. D. (2014). Beyond neuropathic pain:
Gabapentin use in cancer pain and perioperative pain. The Clinical Journal of Pain,
30(7), 613-629.

GABAPENTIN ADMINISTRATION

28

GABAPENTIN ADMINISTRATION

29

GABAPENTIN ADMINISTRATION

30

GABAPENTIN ADMINISTRATION

31

GABAPENTIN ADMINISTRATION

32

GABAPENTIN ADMINISTRATION

33

